Cimifugin is a bioactive component of Saposhnikovia divaricata, a Chinese herb for treating
allergy. Our previous studies demonstrated that
cimifugin inhibited allergic
inflammation efficiently. This study aims to determine the mechanism of
cimifugin on epithelial cells in allergic
inflammation. Mice were sensitized and challenged with
FITC to establish type
2 atopic dermatitis (AD) model. The initial stage of AD model, in which mice were just sensitized with
FITC, was established in vivo and immortalized human epidermal (HaCaT) cells were utilized in vitro. Initiative key
cytokines, TSLP and
IL-33, were measured by ELISA, the junctions in ECs were observed by electron microscopy and TJs (CLDN-1,
occludin and CLDND1) were assessed by Western blot, immunohistochemistry and immunofluorescence. The results showed that TSLP and
IL-33 were inhibited significantly by
cimifugin in the initial stage of AD model. Simultaneously,
cimifugin reduced the separated gap among the epithelial cells and increased the expression of TJs. Similar effects on TSLP/IL-33 and TJs were obtained in vitro. The effect of
cimifugin on TSLP decreased significantly when expression of CLDN1 was interfered with
siRNA and this implied
cimifugin inhibits initiative
cytokines through restoring TJs. Furthermore,
cimifugin administered only in the initial stage obviously attenuated the ultimate allergic
inflammation, which indicate that impacts of
cimifugin in the initial stage on TSLP/IL-33 and TJs are sufficient for suppressing allergic
inflammation. This study not only revealed the mechanisms of
cimifugin, but also indicated the possibility of initiative key
cytokines and TJs as therapeutic targets.